Top 5 Drug Type | Count |
---|---|
Antibody fusion proteins | 10 |
Biological products | 6 |
Biosimilar | 4 |
Colony-stimulating factors | 3 |
Enzyme | 3 |
Target |
Mechanism IDS stimulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. Japan |
First Approval Date23 Mar 2021 |
Target |
Mechanism adrenergic receptor agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. Australia |
First Approval Date03 Mar 2017 |
Target- |
Mechanism Cell replacements |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. Canada |
First Approval Date02 May 2014 |
Start Date05 Nov 2024 |
Sponsor / Collaborator |
Start Date04 Oct 2023 |
Sponsor / Collaborator |
Start Date22 Feb 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Pabinafusp Alfa ( IDS x TfR1 ) | Mucopolysaccharidosis II More | Approved |
Somatropin (genetical recombination)(JCR) ( GHR ) | Small-for-dates baby More | Approved |
Darbepoetin alfa biosimilar(JCR Pharmaceuticals Co., Ltd.) ( EPO receptor ) | Anemia of renal disease More | Approved |
Mirimostim ( CSF-1R ) | Neutropenia More | Approved |
Epoetin kappa(JCR Pharmaceuticals) ( EPO receptor ) | Anemia of renal disease More | Approved |